GO
Loading...

Teva Pharmaceutical Industries Ltd

More

  • Shares of Mylan NV rose $2.98, or 4.5 percent, to $69.82. Earlier this month Mylan offered to buy generic drug and ingredients maker Perrigo for about $29 billion, or $205 per share. Perrigo, which is based in Ireland, said it would review Mylan's offer.

  • The generic, called Glatopa, is made by Sandoz, a unit of Swiss drug company Novartis AG, and U.S.-based Momenta Pharmaceuticals. The Food and Drug Administration approved the drug Thursday. But Teva Pharmaceutical Industries, which makes Copaxone, has said it expects generic versions of the drug to go on sale in the U.S. in September.

  • Mylan seeks to buy Perrigo for $205 per share Wednesday, 8 Apr 2015 | 11:40 AM ET
    Mylan headquarters in Canonsburg, Pa.

    Perrigo shares shot higher after news that Mylan proposed to buy Perrigo for $205 per share.

  • Early movers: MRH, JCI, DHI, PHG, TEVA, CVC & more Tuesday, 31 Mar 2015 | 7:51 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • *China shares hit seven-year high on ambitious Silk Road project. Also Monday, Israel's Teva Pharmaceutical Industries said it would buy U.S. biopharmaceutical firm Auspex Pharmaceuticals Inc for $3.5 billion, and Ireland's Horizon Pharma Plc agreed to buy U.S. drugmaker Hyperion Therapeutics Inc for about $1.1 billion. Earlier, China unveiled details of an...

  • Stocks surge 1%; Dow up over 250 points Monday, 30 Mar 2015 | 4:00 PM ET
    A trader works on the floor of the New York Stock Exchange.

    U.S. stocks closed more than 1 percent higher on Monday amid encouraging talk of stimulus in Asia, as investors eyed the week's economic data.

  • Merger Monday is back: What to buy Monday, 30 Mar 2015 | 11:44 AM ET

    This year is on track to surpass the record set in 2014 for M&A. "Merger Monday" is back. Here's how to trade it.

  • US stocks look set for another rebound, data eyed Monday, 30 Mar 2015 | 8:30 AM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stock index futures indicated a sharply higher open on Monday, following European stocks' move upwards, ahead a data-packed week.

  • Early movers: CTRX, ASPX, DD, ALTR, MSG & more Monday, 30 Mar 2015 | 7:58 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Teva to buy Auspex for $101/share in cash Monday, 30 Mar 2015 | 7:09 AM ET
    An employee collects newly-manufactured pills at Teva Pharmaceutical Industries headquarters in Jerusalem, Israel.

    Teva said the deal would add a portfolio of drugs for the treatment of central nervous system disorders.

  • Three trades to go before the closing bell Monday, 16 Mar 2015 | 1:58 PM ET

    The "Halftime Report" traders give their trades for the second half.

  • CVS: Copycat drugs may bring price cuts of 40-50% Thursday, 12 Mar 2015 | 7:14 AM ET

    Copycat biotech drugs in the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, said a top CVS Health exec.

  • March 2- U.S. generic drug maker Mylan Inc is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week. The company forecast 2015 revenue of $9.6 billion to $10.1 billion and adjusted earnings of $4 to $4.30 per share. The company said it still expects to launch a...

  • *Q4 adjusted EPS $1.31, in line with expectations. TEL AVIV, Feb 5- Teva Pharmaceutical Industries is ready to return to making acquisitions, it said on Thursday, after a year of focusing on costs under its new chief executive. The company posted fourth-quarter earnings of $1.31 per diluted share, excluding one-time items, against $1.42 a year earlier.

  • Teva Pharm Q4 profit, revenue meet expectations Thursday, 5 Feb 2015 | 7:38 AM ET

    TEL AVIV, Feb 5- Teva Pharmaceutical Industries reported quarterly profit that met analysts' estimates on Thursday and reaffirmed its earnings forecast for the full year. Teva, the world's largest generic drugmaker and Israel's biggest company, earned $1.31 per diluted share excluding one-time items in the fourth quarter, compared with $1.42 a year earlier.

  • Stocks close up sharply, boosted by Greece and oil Monday, 2 Feb 2015 | 4:00 PM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed sharply higher on encouraging news from the Eurozone and stronger oil prices.

  • Jan 26- The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug. Nexium raked in about $1.9 billion in global sales in the first half of 2014, according to AstraZeneca's latest earnings statement.

  • WASHINGTON, Jan 26- The U.S. Supreme Court on Monday sent three patent cases, including one dispute over Shire Plc's Lialda drug, back to a lower court for further proceedings in light of a ruling the justices issued last week. Watson Pharmaceuticals, U.S. Supreme Court, No. 14-206.. Butamax Advanced Fuels LLC and Lighting Ballast Control LLC v.

  • Midday movers: Teva, Outerwall, Tiffany & more Tuesday, 20 Jan 2015 | 1:16 PM ET

    Some of Tuesday's midday movers:

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product. In a 7-2 vote, the justices sent the case back to the U.S. Court of Appeals for the Federal...